Perineural Versus IV Dexmedetomidine as Adjuvant to Quadratus Lamborum Block for Pediatrics Undergoing Pyeloplasty
Pain, Postoperative
About this trial
This is an interventional prevention trial for Pain, Postoperative focused on measuring quadratus - dexmedetomidine- bupivavaine- perineural
Eligibility Criteria
Inclusion Criteria:
- paediatrics
- 8-13 years old
- ASA I-II
- laparoscopic pyeloplasty
Exclusion Criteria:
- developmental delay or mental retardation
- parent refusal
- history of allergic reactions to local anesthetics
- infection at the injection site bleeding disorders history of cardiac, neurological, impaired renal function defined by s-creatinine >150 μmol/L
Sites / Locations
- Ain shams university
Arms of the Study
Arm 1
Arm 2
Sham Comparator
Active Comparator
Quadratus lamborum dexmedetomidine intravenous group
Quadratus lamborum dexmedetomidine perineural group
Patients will receive quadratus lamborum block on the same surgical side.a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
Patients will receive quadratus lamborum block on the same surgical side. Patients will receive perineural dexmedetomidine of 1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.